drugset
drugset / Trial / NCT05207670

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies

NCT05207670 ↗

Phase 2 Active not recruiting 320 enrolled Genentech, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin's lymphoma \[NHL\]).

Timeline

Start
2022-02-01
Primary completion
2027-07-31
Completion
2027-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Mosunetuzumab Monoclonal antibody — Subcutaneous
Background Tocilizumab Monoclonal antibody — —

Indications

non-Hodgkin lymphoma